>>WASHINGTON -(Dow Jones)- Amgen Inc. (NasdaqNM:AMGN - News) said discussions with Tularik Inc. (NasdaqNM:TLRK - News; TLRK), about a possible business combination have terminated without resulting in any agreements, according to a regulatory filing.
Such discussions could resume, the company said in an amended Schedule 13D filed Thursday with the Securities and Exchange Commission (News - Websites).
"From time to time representatives of Amgen and (Tularik) have engaged in preliminary discussions concerning a possible business combination. In each case, such discussions were terminated at a preliminary stage without resulting in any agreements," the company said.
"Subject to the requirements of the confidentiality agreement and standstill, such discussions could be renewed at any time in the future, the outcome of which would depend on the parties' ability to reach agreement on pricing, structure and other terms," the filing said.
As reported, the two companies entered into a collaboration agreement on May 21. Under the agreement Amgen and Tularik agreed to consider collaborating on discovery and development of anticancer agents.
According to Thursday's filing, Amgen Inc. holds a 10.81% stake in Tularik, which develops oral drugs that use gene regulation to treat such conditions as diabetes, cancers, cytomegalovirus, obesity and inflammatory diseases.
Shares of the company's common stock closed Thursday at $9.25 each. <<
Cheers, Tuck |
